AU5680900A - Combination of mtp inhibitors and hmg-coa reductase inhibitors and the use thereof in medicaments - Google Patents

Combination of mtp inhibitors and hmg-coa reductase inhibitors and the use thereof in medicaments

Info

Publication number
AU5680900A
AU5680900A AU56809/00A AU5680900A AU5680900A AU 5680900 A AU5680900 A AU 5680900A AU 56809/00 A AU56809/00 A AU 56809/00A AU 5680900 A AU5680900 A AU 5680900A AU 5680900 A AU5680900 A AU 5680900A
Authority
AU
Australia
Prior art keywords
inhibitors
hmg
medicaments
combination
coa reductase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU56809/00A
Inventor
Hilmar Bischoff
Rudi Grutzmann
Ulrich Muller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU5680900A publication Critical patent/AU5680900A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU56809/00A 1999-06-25 2000-06-13 Combination of mtp inhibitors and hmg-coa reductase inhibitors and the use thereof in medicaments Abandoned AU5680900A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19929065 1999-06-25
DE19929065A DE19929065A1 (en) 1999-06-25 1999-06-25 Synergistic drug combination, especially for treating cardiovascular diseases associated with metabolic disorders, comprising bi- or tricyclic aza-heterocyclic MTP inhibitor and HMG-CoA reductase inhibitor
PCT/EP2000/005410 WO2001000183A2 (en) 1999-06-25 2000-06-13 COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS

Publications (1)

Publication Number Publication Date
AU5680900A true AU5680900A (en) 2001-01-31

Family

ID=7912459

Family Applications (1)

Application Number Title Priority Date Filing Date
AU56809/00A Abandoned AU5680900A (en) 1999-06-25 2000-06-13 Combination of mtp inhibitors and hmg-coa reductase inhibitors and the use thereof in medicaments

Country Status (12)

Country Link
EP (1) EP1196194A2 (en)
JP (1) JP2003503342A (en)
AR (1) AR028996A1 (en)
AU (1) AU5680900A (en)
CA (1) CA2376881A1 (en)
DE (1) DE19929065A1 (en)
DO (1) DOP2000000022A (en)
GT (1) GT200000099A (en)
PE (1) PE20010302A1 (en)
SV (1) SV2004000109A (en)
UY (1) UY26218A1 (en)
WO (1) WO2001000183A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10030375A1 (en) * 2000-06-21 2002-01-03 Bayer Ag Use of MTP inhibitors to lower ppTRL
ZA200502496B (en) * 2002-02-28 2005-10-12 Japan Tobacco Inc Ester compound and medicinal use thereof.
JP4832897B2 (en) * 2003-08-29 2011-12-07 日本たばこ産業株式会社 Ester derivatives and their pharmaceutical uses
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
FR2884831B1 (en) * 2005-04-22 2007-08-10 Merck Sante Soc Par Actions Si METHOD FOR SCREENING MTP INHIBITORY COMPOUNDS
DE102011007272A1 (en) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Branched 3-phenylpropionic acid derivatives and their use
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
CN109053927A (en) * 2018-08-08 2018-12-21 中山大学 A kind of amphipathic sodium alginate derivative of the group containing vitamin B12 and its preparation method and application

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4435477A1 (en) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indole and -azaindole derivatives
DE19546918A1 (en) * 1995-12-15 1997-06-19 Bayer Ag Bicyclic heterocycles
DE19546919A1 (en) * 1995-12-15 1997-06-19 Bayer Ag N-heterocyclically substituted phenylacetic acid derivatives
DE19615265A1 (en) * 1996-04-18 1997-12-04 Bayer Ag New pyridazino, pyrimido, pyrazino and triazinoindoles
JP3270764B2 (en) * 1996-11-27 2002-04-02 ファイザー・インク Apo B-secretion / MTP inhibitory amide
AU748608B2 (en) * 1997-05-01 2002-06-06 Bristol-Myers Squibb Company MTP inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels

Also Published As

Publication number Publication date
UY26218A1 (en) 2001-01-31
JP2003503342A (en) 2003-01-28
EP1196194A2 (en) 2002-04-17
SV2004000109A (en) 2004-05-07
PE20010302A1 (en) 2001-04-12
AR028996A1 (en) 2003-06-04
DOP2000000022A (en) 2008-08-15
DE19929065A1 (en) 2000-12-28
GT200000099A (en) 2001-12-13
WO2001000183A3 (en) 2001-05-10
CA2376881A1 (en) 2001-01-04
WO2001000183A2 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
AU2002213357A1 (en) Variant igg3 rituxan r and therapeutic use thereof
AU4055600A (en) Impaction substrate and methods of use
AU5826100A (en) Benzazepinones and quinazolines
ZA200306488B (en) Benzamides and related inhibitors of factor Xa.
AU2001265008A1 (en) Caspase inhibitors and uses thereof
PL356066A1 (en) Caspase inhibitors and uses thereof
AU2002338806A1 (en) Pharmaceutical combinations of pde-v inhibitors and other agents
AU6340600A (en) Telomerase inhibitors and methods of their use
GB9827391D0 (en) Aldose reductase inhibitors and pharmaceutical compositions
EP1039593A3 (en) Laser amplifier and laser oscillator
AU2841801A (en) Triazolotriazinones and the use thereof
AU7271600A (en) Quinazolinone and azaquinazolinone derivatives
AU2002308891A1 (en) Novel heterocyclic derivatives and medicinal use thereof
AU5680900A (en) Combination of mtp inhibitors and hmg-coa reductase inhibitors and the use thereof in medicaments
AU1824201A (en) Polymorphisms in the human HMG-COA reductase gene
AU2001232809A1 (en) Gyrase inhibitors and uses thereof
AU2131601A (en) Eukaryotic initiation factor 4e inhibitors and their use as herbicides
AU1053501A (en) Polyazanaphthalene compound and medicinal use thereof
AU5220800A (en) Combination of mtp inhibitors and lipid reducers and the use thereof in medicaments
AU5569200A (en) Uracil compounds and use thereof
AU5682900A (en) Combination of mtp inhibitors and active agents that influence the metabolism and use thereof in medicaments
AU2669201A (en) Taccalonolides and their use
AU5979300A (en) Angiopoietin-6 and uses thereof
HUP0201597A3 (en) Antilipemic combunations comprising hmg-coa reductase inhibitors and carnitines
AU5974100A (en) 6-carboxyphenyldihydropyridazinone derivatives and use thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase